Cel-Sci Corp
Research Cel-Sci Corp (CVM) on Bullrun: market cap USD 34.12M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCVM
- ExchangeNYSE MKT
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 34.12M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 5.67M
- Free cash flow-USD 4.03M
Valuation Snapshot
latest market cap is USD 34.12M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 25.41M | -USD 17.16M | n/a | -6.27 | USD 10.95M | USD 9.38M | USD 15.96M |
| FY2024 | USD 0 | -USD 26.92M | -USD 18.91M | n/a | -15.31 | USD 4.74M | USD 11.62M | USD 12.87M |
| FY2023 | USD 0 | -USD 32.37M | -USD 23.21M | n/a | -0.73 | USD 4.15M | USD 13.57M | USD 13.21M |
| FY2022 | USD 0 | -USD 36.70M | -USD 18.88M | n/a | -0.87 | USD 22.67M | USD 15.30M | USD 32.16M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 34.12M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 44.23M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 29.23M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 135.95M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 102.65M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 307.15M | n/a | n/a | n/a |
About Cel-Sci Corp
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cel-Sci Corp's market cap?
Cel-Sci Corp's market capitalization is USD 34.12M.
What does Cel-Sci Corp do?
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.